We have shown recently that a 15 -mer phosphorothioate oligodeoxynucleotide ( ODNas750 / 15 ) that hybridizes to the ( CAG )n polyglutamine region of mRNA encoding human androgen receptor ( AR ) inhibits the expression of AR in LNCaP prostate cancer cells in vitro. This AR downregulation was accompanied by significant cell growth inhibition and reduced PSA secretion. In the present study we investigated the effects of this antisense AR ODN on prostate tumor growth in vivo using a mouse xenograft model. Via subcutaneously implanted diffusion pumps, either ODNas750 / 15 or a scrambled control sequence ODNsr750 / 15 was continuously administered into LNCaP tumor -bearing male nude mice for 7 weeks. Compared with untreated control animals, treatment with ODNas750 / 15 resulted in significant tumor growth inhibition. Retardation of tumor growth was also significant in castrated mice, whereas the scrambled control ODN did not exert any effects. No side effects such as loss of body weight were observed at any time of treatment. ODN treatment was well tolerated and, in contrast to castration, did not induce shrinkage of mouse prostates. Both AR expression in the tumor and PSA levels in mouse serum correlated with tumor size. However, we failed to demonstrate a correlation between tumor retardation and Ki -67 antigen expression and the number of apoptotic cells, respectively. Testing of antisense -treated LNCaP cells revealed that expression levels of other proteins that contain shorter polyglutamine sequence stretches such as HDAC2, TFIID, and c -jun were not affected. The present study demonstrates that downregulation of AR with antisense ODNas750 / 15 causes prostate tumor growth inhibition. These results further point out the important role of the AR in prostate tumors and support further testing of AR downregulation for treatment of prostate cancer.
O ne of the main features of human prostate cancer is its heterogeneity characterized by varying progression rates as well as responses to therapies. Generally, radical prostatectomy is the main kind of treatment for organconfined prostate cancer. By contrast, non -organ confined or advanced prostate disease is preferably treated by androgen ablation therapy, resulting in a reduction of androgen levels in the circulation. As most prostate tumors are androgen dependent at the time of diagnosis, 1, 2 androgen withdrawal by administration of drugs such as luteinizing hormone-releasing hormone (LHRH ) antagonists or antiandrogens, or by surgical castration results in induction of programmed cell death. 3 However, all these therapies become inefficient upon tumor progression that is associated with androgen-independent growth of tumor cells. As progression to androgen independency occurs in the majority of prostate tumors during therapy, intensive research has focused on the development of novel strategies for the treatment of advanced prostate cancer in the past.
One promising approach is the highly selective inhibition of protein expression by the use of antisense oligodeoxynucleotides (ODNs ) targeting various genes being involved in cancer progression. Antisense ODNs bind to their complementary target mRNA resulting in a degeneration of template gene activity. 4, 5 Some of these ODNs have already been tested both in vitro and in vivo. 6 -10 Recently, we have shown that downregulating the human androgen receptor ( AR ) with an antisense AR ODN directed against the N -terminal polyglutamine region of the AR -encoding gene causes significant inhibition of LNCaP prostate cancer cell growth in vitro. 11 These results provided further evidence to support the apparently important functional role of the AR in androgen -independent prostate tumor growth. Reports about mutations converting the AR into a promiscuous receptor, 12 ligand -independent AR activation by a number of growth factors, 13 -15 as well as the detection of AR gene amplifications 16 suggest a potential role of the AR in maintaining the growth of prostate tumor cells.
In this report, we have investigated the effects of the antisense ODN targeting the AR polyglutamine repeatencoding sequence in a LNCaP xenograft tumor model. The results support the concept of AR downregulation as a promising method for treatment of prostate cancer.
Materials and methods

Oligonucleotides
On the basis of the sequence of the human AR cDNA, we designed a 15 -base phosphorothioate antisense ODN ( ODNas750 /15, 5 0 -GTC GTC GTC GTC GTC -3 0 ) targeting the N -terminal polyglutamine encoding CAG triplet repeat region. A ''scrambled'' phosphorothioate ODN served as negative control (ODNsr750 /15, 5 0 -TTG CAG CTG ATG CTA -3 0 ). HPSF -purified ODNs were purchased from MWG -Biotech ( Ebersberg, Germany ) and dissolved in distilled water.
Cell lines and tumor growth
LNCaP cells were obtained from the American Type Culture Collection (Bethesda, MD ) at passage 21. Cells were grown in RPMI medium supplemented with 10% fetal calf serum and antibiotics at 378C in an atmosphere of 5% CO 2 in air and routinely passaged with trypsin /EDTA. Medium was changed every other day.
Six -week -old male athymic (nude ) mice (NMRI strain, M&B, Bomholdtgard, Denmark) were supplemented with testosterone pellets ( 12.5 mg, 90-day release; IRA, Sarasota, FL ). LNCaP cells (1.5Â10 6 ) suspended in a 1:1 mixture of RPMI 1640 medium and Matrigel were injected subcutaneously into the left flank of each animal. Treatment was started when tumors reached a size of 20-25 mm 2 .
Animal treatment
Mice were randomly assigned to four different experimental groups of eight animals each. One group received the antisense AR ODNas750 / 15, suspended in 0.1 mL water ( 9 mg / kg mouse per day ). Control animals were treated with vehicle or ODNsr750 / 15. Oligonucleotides were supplied by ALZET minipumps that were surgically implanted subcutaneously in the vicinity of the tumors. The pumps were replaced every 2 weeks. The fourth group of animals were orchiectomized and not replaced with testosterone pellets. Tumor size was determined weekly using a caliper and expressed as tumor area (lengthÂwidth ) in square millimeters ( mm 2 ). After 7 weeks of treatment, selected organs (LNCaP tumors, prostates, and seminal vesicles ) were harvested and weighed. For immunohistochemical studies, tissue samples were routinely fixed in formalin, embedded in paraffin, and stained with hematoxylin and eosin. 17 Blood samples were collected and PSA levels were measured by microparticle enzyme immunoassay ( MEIA ) as recommended by the manufacturer (Abbott IMX, Abbott Laboratories, Abbott Park, IL ).
Immunohistochemistry
Tissue sections were deparaffinized in xylene and rehydrated in serial alcohol dilutions. Staining was performed according to a streptavidin -biotin -peroxidase protocol using a mouse monoclonal anti -hAR antibody (clone F39.4; BioGenex Laboratories, San Ramon, CA ), 17 a mouse monoclonal anti -Ki -67 antibody (DAKO, Glostrup, Denmark), and a rabbit polyclonal anti -HDAC2 antibody ( Santa Cruz Biotechnology, Santa Cruz, CA ), respectively. AR levels were determined by a semiquantitative evaluation on the basis of a four-point scale by a pathologist (0, negative staining; + , weak staining; + +, positive staining; + + +, very strong staining ). Percentage of Ki -67 antigen-expressing cells was determined by counting the number of positive nuclei per visual field at a magnification of 200-fold.
Apoptosis assay
Apoptotic cells were detected via terminal deoxynucleotidyl transferase -mediated deoxyuridine -triphosphate -biotin nick end labeling (TUNEL ) assay using the DNA fragmentation ApopTag 1 in situ apoptosis detection kit ( Intergen, Purchase, NY ). This kit is based on the labeling of the 3 0 -OH termini that are generated on DNA fragmentation with modified nucleotides by terminal deoxynucleotidyl transferase (TdT ). Briefly, paraffinembedded tissue was deparaffinized with xylene, digested with proteinase K (20 g/ mL ) for 15 5 minutes. After labeling for 1 hour at 378C, slides were incubated with antidigoxigenin conjugate and color was developed in peroxidase substrate. Slides were counterstained with methyl green and analyzed by transmission light microscopy. Samples incubated with a nucleotide mixture lacking terminal transferase were used as a negative control.
Western blot analysis
LNCaP cells were incubated in RPMI1640 supplemented with 2 mM L -glutamine, 20 mM Hepes, 10% fetal calf serum and increasing concentrations of ODNas750 /15 and a lipofection reagent (4 g /mL NC388, Atugen, Boulder, CO ) for a period of 24 hours. Then, cells were harvested with trypsin /EDTA and lysed in 1Â sample buffer (62 mM Tris -HCl pH 6.8, 10% glycerol, 5% -mercaptoethanol, 1 mg bromphenolblue, 2% sodium dodecyl sulfate [ SDS ] ). Total protein was determined by the method of Bradford.
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Twenty micrograms total protein was run on 12% SDS polyacrylamide gels and subsequently transferred onto polyvinylidene fluoride membranes. Blots were blocked with 5% nonfat milk powder for 1 hour and then incubated overnight with either a 1:500 -diluted mouse monoclonal anti -AR (BioGenex Laboratories ), a 1:500 -diluted rabbit polyclonal anti -TFIID ( Santa Cruz Biotechnology), a 1:500 -diluted rabbit polyclonal anti -HDAC2 (Santa Cruz Biotechnology), a 1:500 -diluted rabbit polyclonal anti -cjun antibody ( Santa Cruz Biotechnology), or a 1:4000 -diluted mouse monoclonal anti -actin antibody ( Chemicon International, Hof heim, Germany ) at 48C. Blots were washed and then incubated for 1 hour with a horseradish peroxidase ( HRP ) -conjugated anti -mouse IgG ( Amersham Life Science, Buckinghamshire, UK ) or an HRP -conjugated anti -rabbit IgG ( Santa Cruz Biotechnology) at room temperature. After washing, the proteins of interest were visualized using an enhanced chemoluminescence Western blotting system (Santa Cruz Biotechnology ).
Statistical analysis
Numerical data are expressed as average ± SEM. The statistical significance of differences was determined by conducting Mann -Whitney U tests. P values <.05 were considered statistically significant. The correlation coefficient r was calculated with Cricket Graph III program ( Computer Associates, Islandia, NY ).
Results
Effects of ODNas750 / 15 on LNCaP prostate tumor growth in vivo
Nude mice bearing LNCaP tumors were treated with an antisense AR ODNas750 /15 using osmotic minipumps that were installed subcutaneously in the vicinity of the tumors. This ODN is directed against the triplet repeat sequences within the AR gene. As the human AR gene sequence contains an exceptionally high number of CAG repeats, the antisense ODN is considered to have a high possibility to bind to its target sequence. In vitro, it was shown recently that treatment with this antisense ODN results in inhibition of LNCaP prostate tumor cell growth and PSA secretion, respectively.
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Oligonucleotides were administered continuously over a period of 7 weeks at a concentration of 9 mg / kg mouse per day. Tumor area was determined weekly and indicated as mm 2 . As shown in Figure 1 , antisense treatment significantly inhibited tumor growth by 52% (76.2 ± 22.4 mm 2 ) compared with vehicle -treated mice (161.4 ± 37.6 mm 2 ; P=.039 ). Treatment of animals with the control ODNsr750 /15 showed only minor effects on tumor growth (139.0 ± 34.7 mm 2 ; P=.605), whereas castration induced significant tumor growth inhibition (23.9 ± 1.5 mm 2 ; P= .009). There were no apparent signs of toxicity in any treatment group, and no significant effects on the animals' body weight ( Table 1) .
At the end of treatment LNCaP tumors, mouse prostates, and seminal vesicles were removed from mice to determine 
LNCaP tumor -bearing nude mice were treated with or without ODNs ( ODNsr750 / 15, scrambled control; ODNas750 / 15, antisense AR ODN ) or castration, respectively. Tumor size was measured with a caliper after 7 weeks of treatment and subdivided according to their sizes into small ( < 100 mm 2 ) and large tumors ( >100 mm 2 ). Stable disease indicates failure of tumor growth during the treatment period of 7 weeks. LNCaP tumors, mouse prostates, and seminal vesicles were harvested and weighed after a treatment period of 7 weeks. Animals were subjected to different treatments: vehicle, castration, negative control ODNsr750 / 15, antisense AR ODNas750 / 15.
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Inhibition of prostate tumor growth in vivo IE Eder et al organ weights. Relative tumor weight was reduced to 43% by treatment with the antisense ODN (175.2± 85.9 mg, n =8 ) compared with vehicle-treated control animals ( 404.9 ± 197.0 mg, n= 6 ) ( Table 1 ) . Three of eight animals showed no tumor growth (stable disease ) and only two of eight animals developed a large tumor (>100 mm 2 ) ( Table 2 ). Castration resulted in significant reduction of relative tumor weight ( 15.1 ± 8.0 mg; P=.028 ) with 100% treatment response.
Antisense treatment did not affect mouse prostates ( 3.0± 0.2 mg ) compared with vehicle-treated control animals (2.9 ± 0.1 mg ). However, castration induced a significant shrinkage of the animals' prostates ( 0.5 ± 0.1 mg, P=.003) ( Table 1 ) 
AR expression is reduced in LNCaP tumors treated with ODNas750 / 15
After 7 weeks of treatment, LNCaP tumors were collected and preserved in formalin or frozen in liquid nitrogen. Tumors were examined immunohistochemically by standard light microscopy after hematoxylin and eosin staining of paraffin-embedded tissue sections. Staining with a mouse monoclonal anti -AR antibody revealed that AR expression levels were low in tumors that responded to treatment either by ODNas750 /15 or by castration with tumor growth retardation ( Fig 2c and d ) . AR expression was high in all vehicle-treated mice (Fig 2a ) and in animals treated with ODNsr750 /15 ( Fig 2b ) , which had developed large tumors. Two animals of the antisense -treated group were not affected by treatment with ODNas750 /15. They developed large tumors with high AR staining levels (data not shown).
Treatment with ODNas750 / 15 reduced PSA serum levels
Similar to AR expression, serum PSA levels were found to correlate with tumor weight as shown in Figure 3 (r= 0.509 ). Animals that were treated with ODNas750 /15 had reduced PSA serum levels (166.6 ± 98.0 ng /mL, n= 8) as compared with vehicle -treated mice (531.7 ± 346.6 ng /mL, n= 5). PSA serum levels were also decreased in castrated animals ( 4.1± 2.1 ng /mL, n=8).
Analysis of expression of apoptosis and proliferation markers in ODNas750 / 15 treated tumors
To determine whether tumor growth inhibition is caused by apoptosis, we performed a TUNEL assay to assess the number of apoptotic cells by DNA laddering. This assay detects free 3 0 ends that are generated by apoptotic DNA cleavage and results in green staining of apoptotic cells. As shown in Figure 4 , neither in the antisense -treated (Fig 4c ) nor in castrated animals ( Fig 4c ) was the number of apoptotic cells significantly increased as compared with vehicle-treated controls (Fig 4a and b) . In general, the number of positively staining cells was very low in all samples rendering a statistical evaluation of the data impossible.
Therefore, we additionally assessed the expression of Ki-67 antigen, a generally used proliferation marker ( Fig 5 ) . There was a correlation between tumor size and Ki-67 antigen expression (r =0.5 ) but there was no significant difference among the treatment groups. 
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Inhibition of prostate tumor growth in vivo IE Eder et al in basic cellular functions such as transcription and replication, for example, histone deacetylase 2 (HDAC2 ), transcription factor IID ( TFIID ), and c -jun. However, their numbers of glutamine residues in the repeat sequence differ and range from 6 to 9 ( c-jun, TFIID and HDAC2 ) compared with 22 in AR. To investigate the effects of ODNas750 / 15 on these proteins, we treated LNCaP cells with increasing concentrations ( 0.1, 0.3, 1.0 M) of the antisense AR ODN. Protein levels were determined 8, 16, and 24 hours afterwards by immunoblotting. As shown in Figure 6 , the AR was downregulated after 16 and 24 hours. By contrast, expression of HDAC2, TFIID and c -jun were not significantly changed neither by treatment with the antisense AR ODNas750 /15 nor with the control ODNsr750 /15. Actin levels were determined as gel loading control.
In agreement with these in vitro results the expression of HDAC2 was not altered in antisense -treated LNCaP tumors in vivo as shown by immunohistochemistry (Fig 7 ) .
Discussion
The present study shows that downregulation of the AR with antisense AR ODNs inhibits the growth of LNCaP prostate tumors in vivo. Antisense ODNs are designed to block the transfer from gene to protein during RNA processing of a specific gene and are therefore a promising new approach to the treatment of malignant diseases. Indeed, a number of different target genes that play an important role in the development and growth of tumor cells have been inhibited with antisense technology. So far, there are several different antisense approaches targeting, for instance, proteins of the intracellular signal transduction pathway like C-raf, 19 -21 protein kinase A, 22 protein kinase C, 23, 24 or JNK, 25 proteins involved in the apoptotic pathway, 26, 27 cell cycle -regulatory proteins 28 or various growth factors like vascular endothelial growth factor and IGF -I. 29, 30 Some of these oligonucleotides are now tested in clinical trials for the treatment of various diseases.
Great efforts have been made in the past to develop novel approaches to the treatment of prostate cancer. The main kinds of treatment for prostate cancer are limited to surgical removal of the tumor-infected organ by radical prostatectomy if the tumor is organ confined or hormonal therapy if the tumor crosses the capsule. One major problem in the treatment of non-organ confined prostate cancer is that the currently available therapies are only palliative. Hormone therapy includes the decrease of androgens in the patients' circulation either with luteinizing hormone -releasing hormone (LHRH ) analogs or with antiandrogens that inactivate the AR. As most prostate cancer cells initially grow androgen dependently, this androgen withdrawal results in apoptosis. 1 -3,31,32 Failure of androgen ablation therapy is likely to result from progression of prostate tumors to androgen independency that may have different reasons. It was shown, for example, that AR expression is not decreased or lost in advanced prostate tumors but instead frequently increased. 16, 33 Furthermore, mutations that convert the AR to a promiscuous receptor that can be activated not only by androgens but also by various other hormones and growth factors have been associated with tumor progression. 12,34 -36 It was also shown that the AR could be activated ligand independently in the absence of hormones by various growth factors such as insulin -like growth factor (IGF -I), keratinocyte growth factor ( KGF ), epidermal growth factor ( EGF ), and cAMP-activating compounds. 13, 14, 37 All these findings point out that prostate tumors may use several pathways to circumvent their androgen requirements to adapt to an androgen -deprived environment. Nevertheless, the key regulatory protein involved both in the androgen -dependent and the androgen -independent growth of prostate tumors seems to be the AR, a transcription factor belonging to the family of steroid receptors that mediates hormonal action. 38 We therefore speculated that the AR might be a potential target for antisense therapy and designed an ODN to inhibit a key regulatory step in the androgen signal cascade. We tested various phosphorothioate ODNs that were directed against the translation start region, the GGC repeats encoding polyglycine, and the CAG repeats encoding polyglutamine region, respectively. 11 As the ODNs that targeted the translation start region of the AR gene did not have a significant effect on AR expression we designed antisense ODNs directed against the triplet -repeat sequences within the AR gene. We considered that a 15 -base ODN would have the possibility to bind several times in a triplet -repeat target sequence resulting in a more potential antisense effect. And indeed, using these antisense oligonucleotides, we were able to show a significant reduction of AR levels in LNCaP prostate cancer cells in vitro, associated with significant inhibition of cell proliferation and significant reduction of PSA secretion. 11 Both antisense oligonucleotides targeting one of the repeat regions were equally effective in cultured LNCaP cells and we have chosen the poly -GAG targeting ODN for further evaluation in the in vivo study. In vivo, this antisense AR ODN has similar effects as shown in the present study using a prostate tumor xenograft model. Treatment of LNCaP tumor -bearing nude mice resulted in significant inhibition of prostate tumor growth and reduced serum PSA levels. In accordance, AR levels were reduced in tumors that responded to antisense therapy. A scrambled control ODN with the same base composition as the antisense ODN did not have any effects on tumor growth and on AR expression in tumor tissue, respectively. ODN treatment was generally well tolerated by all animals. This is important in view of the fact that our antisense ODN contains a relatively high content of CpG motifs. Such DNA motifs might be able to stimulate the immune system by inducing B -cell proliferation and production of Th -1 type cytokines. 39 Inflammatory reactions, typical signs of sequence -independent, non -antisense actions caused by ODN treatment 40 -42 were not observed. Furthermore, mice did not show any reaction on the subcutaneously installed ALZET diffusion pumps. These were chosen to guarantee a continuous systemic administration of oligonucleotides, a commonly used method for antisense treatment in vivo. 43, 44 As the antisense AR ODN is directed against the CAG triplet repeat region in the N -terminal sequence of the receptor, it must be considered that other proteins that have a polyglutamine sequence encoded by poly -CAG may be affected. A BLAST search revealed that the number of , and 5 CAG triplet repeats, respectively. The 15 -bases -long antisense ODN therefore has a possibility to bind once within the sequence of these proteins. By contrast, up to four antisense AR ODN molecules can bind within the 22 CAG repeats of the AR sequence in LNCaP cells. We speculate that ODNas750 /15 is more potent on the AR than on the other targets because of the multiplicity of its binding sites within the target sequence of the AR. Besides, differences in protein stability and in the accessibility of the target sequence in the genes investigated and in the AR might also contribute to the differences observed.
Castration also induced significant tumor growth retardation in our animal model. As expected, PSA serum levels were also reduced. AR expression levels were significantly decreased in tumors of castrated mice. This has been shown recently by other groups that demonstrated a reduction of AR levels following androgen deprivation. 47, 48 Castration treatment also caused a significant shrinkage of prostate and seminal vesicles, whereas antisense treatment inhibited growth of the LNCaP tumors but did not significantly affect the animals' prostates. Seminal vesicles were affected by antisense treatment, however, the effect was small and there was a similar effect by the scrambled control ODNsr750 / 15. We therefore tempted to speculate that this reduction in organ weight is hardly due to downregulation of the AR. This difference is expected in view of the sequence differences between the mouse and the human AR, especially within the polyglutamine target sequence. The mouse AR mRNA contains only one antisense AR ODN binding site (5 CAG repeats), which probably is not sufficient to exert a potent downregulating antisense effect. Thus, the effect on mouse AR is similar to the effect observed on human proteins with a short polyglutamine sequence.
In vivo, ODN activity did not require the presence of a delivery system although in vitro, inhibition of AR expression was only achieved by electroporation or lipophilic transfection. ODNs were administered continuously via subcutaneously installed diffusion pumps. These small pumps were implanted in the vicinity of the tumors and did not show any toxicity. Diffusion pumps have already been used by several other groups and were generally found to be nontoxic to the animals. 44 They were also well tolerated in this study; however, one critical parameter may be uptake of the ODN into tumor cells. Even if the diffusion pumps were installed in close vicinity of the tumors, insufficient delivery and ODN uptake in some of the animals cannot be excluded. This might be one explanation for the failure of therapy in two animals of the antisense -treatment group, which developed large tumors. These mice did not respond and also had strong AR expression in tumor tissue, indicating that there was no AR downregulation by the antisense ODN.
The mechanisms underlying tumor growth inhibition is not clear. One possibility is an increased rate of apoptosis. In vitro, we have shown that treatment of LNCaP cells with ODNas750 / 15 induces apoptosis. However, in vivo, when examining the tumors after 7 weeks of treatment we did not find evidence for elevated apoptosis rates by TUNEL staining of tumor samples. Similar results were found by Agus and coworkers who failed to show apoptosis after tumor remission by androgen withdrawal in the CWR22 xenograft model. 49 In that study expression of the proliferation marker Ki -67 was dramatically decreased by androgen deprivation. Therefore, Agus et al postulated that tumor remission was not caused by apoptosis but rather by the fact that the cells enter a viable but nonproliferative state. In our study, we did not find a correlation between tumor growth and Ki-67 antigen expression neither in the antisensetreated nor in the castrated group of mice. This might be explained by the slow growth of LNCaP tumors and the general low number of Ki -67 positive cells in these tumors that complicate analysis of small differences.
In summary, this study shows that inhibition of AR expression results in significant prostate tumor growth inhibition in vivo. These promising results further point out the key role of the AR in prostate tumor growth and warrant further testing of AR downregulation as a treatment for prostate cancer.
